JP2011523347A5 - - Google Patents

Download PDF

Info

Publication number
JP2011523347A5
JP2011523347A5 JP2010544350A JP2010544350A JP2011523347A5 JP 2011523347 A5 JP2011523347 A5 JP 2011523347A5 JP 2010544350 A JP2010544350 A JP 2010544350A JP 2010544350 A JP2010544350 A JP 2010544350A JP 2011523347 A5 JP2011523347 A5 JP 2011523347A5
Authority
JP
Japan
Prior art keywords
alphavirus
attenuated
subgenomic
virus
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010544350A
Other languages
English (en)
Japanese (ja)
Other versions
JP5758632B2 (ja
JP2011523347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000458 external-priority patent/WO2009131604A2/en
Publication of JP2011523347A publication Critical patent/JP2011523347A/ja
Publication of JP2011523347A5 publication Critical patent/JP2011523347A5/ja
Application granted granted Critical
Publication of JP5758632B2 publication Critical patent/JP5758632B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010544350A 2008-01-24 2009-01-23 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用 Expired - Fee Related JP5758632B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6222908P 2008-01-24 2008-01-24
US61/062,229 2008-01-24
PCT/US2009/000458 WO2009131604A2 (en) 2008-01-24 2009-01-23 Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Publications (3)

Publication Number Publication Date
JP2011523347A JP2011523347A (ja) 2011-08-11
JP2011523347A5 true JP2011523347A5 (enExample) 2014-06-19
JP5758632B2 JP5758632B2 (ja) 2015-08-05

Family

ID=41217313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010544350A Expired - Fee Related JP5758632B2 (ja) 2008-01-24 2009-01-23 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用

Country Status (15)

Country Link
US (3) US8426188B2 (enExample)
EP (2) EP3085787B1 (enExample)
JP (1) JP5758632B2 (enExample)
KR (2) KR101668849B1 (enExample)
CN (1) CN102083986B (enExample)
AU (1) AU2009238667A1 (enExample)
CA (2) CA2713165C (enExample)
CO (1) CO6290702A2 (enExample)
IL (2) IL207167A (enExample)
MX (3) MX367792B (enExample)
MY (1) MY178870A (enExample)
NZ (2) NZ587502A (enExample)
SG (2) SG187513A1 (enExample)
WO (1) WO2009131604A2 (enExample)
ZA (1) ZA201005943B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2183368T3 (en) * 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
CN102083986B (zh) 2008-01-24 2014-06-18 德克萨斯大学系统董事会 不能在蚊子中复制的减毒重组甲病毒及其用途
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
US9701719B2 (en) 2012-09-27 2017-07-11 Research Development Foundation Attenuated Chikungunya virus
US10137186B2 (en) 2013-03-14 2018-11-27 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
JP2019509750A (ja) * 2016-03-31 2019-04-11 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 生弱毒化アルファウイルス構築物及び方法、ならびにそれらの使用
US11090384B2 (en) * 2016-05-27 2021-08-17 Griffith University Arthrogenic alphavirus vaccine
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
WO2020028749A1 (en) * 2018-08-03 2020-02-06 Uab Research Foundation Methods and compositions for alphavirus vaccine
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
MX2022007905A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2327189A1 (en) * 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
KR101518309B1 (ko) * 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
US7603447B2 (en) 2004-07-30 2009-10-13 Research In Motion Limited Method and system for coordinating device setting between a communications client and its host device
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
CA2579507C (en) 2006-03-15 2017-06-13 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
CN102083986B (zh) 2008-01-24 2014-06-18 德克萨斯大学系统董事会 不能在蚊子中复制的减毒重组甲病毒及其用途

Similar Documents

Publication Publication Date Title
US12331076B2 (en) Alphavirus-based replicons for administration of biotherapeutics
Sun et al. Stable, high-level expression of reporter proteins from improved alphavirus expression vectors to track replication and dissemination during encephalitic and arthritogenic disease
US20230126773A1 (en) Recombinant virus replicon systems and uses thereof
Gardner et al. Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis
Frolov et al. Translation of Sindbis virus mRNA: analysis of sequences downstream of the initiating AUG codon that enhance translation
CN1989250B (zh) Tc-83衍生的甲病毒属载体、颗粒和方法
JP5758632B2 (ja) 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用
JP2017522907A5 (enExample)
Gorchakov et al. Selection of functional 5′ cis-acting elements promoting efficient Sindbis virus genome replication
JP2021511318A (ja) 組換えレプリコン系を使用する免疫応答の誘導および増強
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
Wirblich et al. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV
TWI769467B (zh) 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途
JP2017503482A5 (enExample)
Flick et al. Functional analysis of the noncoding regions of the Uukuniemi virus (Bunyaviridae) RNA segments
JP2019509750A5 (enExample)
JP2004501646A5 (enExample)
de Haan et al. Coronaviruses as vectors: stability of foreign gene expression
CN111744000A (zh) 免疫抑制功能降低的口蹄疫重组病毒及其制备方法与应用
JP2017515509A (ja) ワクチン用途のための高力価ウイルス様ベシクルの進化の方法
Urban et al. Major capsid protein synthesis from the genomic RNA of feline calicivirus
Kim et al. Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype
Strauss et al. Molecular genetic evidence that the hydrophobic anchors of glycoproteins E2 and E1 interact during assembly of alphaviruses
Harouaka et al. Second-site mutations selected in transcriptional regulatory sequences compensate for engineered mutations in the vesicular stomatitis virus nucleocapsid protein
EP1029069B1 (en) Alphavirus vectors